Literature DB >> 2333294

Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain.

Y Devash1, T A Calvelli, D G Wood, K J Reagan, A Rubinstein.   

Abstract

Many, but not all, infants born to mothers infected with the human immunodeficiency virus (HIV) are infected in utero. We have now shown that mothers who have high-affinity/avidity antibodies directed toward the principal neutralizing domain (PND) of gp120 are less likely to transmit HIV to their children. An ELISA that preferentially measures the level of the biologically functioning, high-affinity/avidity antibodies against PND is described. In a retrospective study of 15 maternal/neonatal serum samples, the assay correctly identified the 4 uninfected and the 11 HIV-infected infants. Other clinical and laboratory parameters such as p24 antigen, phytohemagglutinin mitogenic index, and absolute surface antigen T4+ cell counts did not accurately predict HIV fetal transmission. In addition to introducing a promising diagnostic tool, this study provides the in vivo evidence that protective antibodies may prevent infection by HIV.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2333294      PMCID: PMC53917          DOI: 10.1073/pnas.87.9.3445

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.

Authors:  T J Matthews; K J Weinhold; H K Lyerly; A J Langlois; H Wigzell; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

2.  Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells.

Authors:  J R Rusche; D L Lynn; M Robert-Guroff; A J Langlois; H K Lyerly; H Carson; K Krohn; A Ranki; R C Gallo; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 3.  The epidemiology of pediatric acquired immunodeficiency syndrome.

Authors:  A Rubinstein; L Bernstein
Journal:  Clin Immunol Immunopathol       Date:  1986-07

4.  Infants born to mothers seropositive for human immunodeficiency virus. Preliminary findings from a multicentre European study.

Authors:  J Q Mok; C Giaquinto; A De Rossi; I Grosch-Wörner; A E Ades; C S Peckham
Journal:  Lancet       Date:  1987-05-23       Impact factor: 79.321

5.  Acquired immunodeficiency with reversed T4/T8 ratios in infants born to promiscuous and drug-addicted mothers.

Authors:  A Rubinstein; M Sicklick; A Gupta; L Bernstein; N Klein; E Rubinstein; I Spigland; L Fruchter; N Litman; H Lee; M Hollander
Journal:  JAMA       Date:  1983-05-06       Impact factor: 56.272

6.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

7.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Authors:  T J Palker; M E Clark; A J Langlois; T J Matthews; K J Weinhold; R R Randall; D P Bolognesi; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

Authors:  J R Rusche; K Javaherian; C McDanal; J Petro; D L Lynn; R Grimaila; A Langlois; R C Gallo; L O Arthur; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

9.  Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

Authors:  T J Matthews; A J Langlois; W G Robey; N T Chang; R C Gallo; P J Fischinger; D P Bolognesi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

10.  HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.

Authors:  S D Putney; T J Matthews; W G Robey; D L Lynn; M Robert-Guroff; W T Mueller; A J Langlois; J Ghrayeb; S R Petteway; K J Weinhold
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

View more
  41 in total

1.  Neutralizing antibodies and antigens in AIDS.

Authors:  S G Norley; R Kurth
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Prediction of optimal peptide mixtures to induce broadly neutralizing antibodies to human immunodeficiency virus type 1.

Authors:  L H Holley; J Goudsmit; M Karplus
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

Review 3.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

4.  Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.

Authors:  K S Cole; J L Rowles; B A Jagerski; M Murphey-Corb; T Unangst; J E Clements; J Robinson; M S Wyand; R C Desrosiers; R C Montelaro
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

Authors:  J E Clements; R C Montelaro; M C Zink; A M Amedee; S Miller; A M Trichel; B Jagerski; D Hauer; L N Martin; R P Bohm
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children.

Authors:  K Broliden; E Sievers; P A Tovo; V Moschese; G Scarlatti; P A Broliden; C Fundaro; P Rossi
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

7.  Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.

Authors:  J P Langedijk; N K Back; E Kinney-Thomas; C Bruck; M Francotte; J Goudsmit; R H Meloen
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine.

Authors:  P Mazzetti; S Giannecchini; D Del Mauro; D Matteucci; P Portincasa; A Merico; C Chezzi; M Bendinelli
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  HIV-I infection in perinatally exposed siblings and twins. The Italian Register for HIV Infection in Children.

Authors:  M de Martino; P A Tovo; L Galli; D Caselli; C Gabiano; P L Mazzoni; A Giacomelli; M Duse; C Fundarò
Journal:  Arch Dis Child       Date:  1991-10       Impact factor: 3.791

10.  Evolution of human immunodeficiency virus type 1 nucleotide sequence diversity among close contacts.

Authors:  H Burger; B Weiser; K Flaherty; J Gulla; P N Nguyen; R A Gibbs
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.